NEW YORK, June 28, 2021 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, announced
it has been added to the Russell 2000®,
Russell 3000® and
Russell Microcap® Indexes effective after
the U.S. markets open today, June 28,
2021, as part of the 2021 Russell US Indexes
Reconstitution.
"The inclusion of Seelos into the Russell 2000, 3000 and microcap indexes should
help increase our exposure in the investment community and is a
tribute to the progress we have made building the company over the
past year," said Raj Mehra, PhD, Chairman and CEO of Seelos.
Membership in the US all-cap Russell 3000® Index, which remains
in place for one year, means automatic inclusion in the large-cap
Russell
1000® Index or small-cap Russell 2000® Index as
well as the appropriate growth and value style indexes. The Russell
Microcap® Index represents 2,000 small cap
and microcap stocks and captures the smallest 1,000 companies in
the Russell
2000®, in addition to 1,000 smaller
U.S.-based listed stocks. FTSE Russell determines membership for
its Russell indexes primarily by
objective, market-capitalization rankings, and style
attributes.
Russell indexes are widely used
by investment managers and institutional investors for index funds
and as benchmarks for active investment strategies. Approximately
$10.6 trillion in assets are
benchmarked against Russell's US
indexes. Russell indexes are part
of FTSE Russell, a leading global index provider.
For more information on the Russell 3000® Index and the
Russell indexes reconstitution, go
to the "Russell Reconstitution" section on the FTSE Russell
website.
About Seelos Therapeutics
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
diseases. The Company's robust portfolio includes several
late-stage clinical assets targeting indications including Acute
Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder
(MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic
lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease,
other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our
website: http://seelostherapeutics.com, the content of which
is not incorporated herein by reference.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 70 countries,
covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$17.9 trillion is currently
benchmarked to FTSE Russell indexes. For over 30 years, leading
asset owners, asset managers, ETF providers and investment banks
have chosen FTSE Russell indexes to benchmark their investment
performance and create ETFs, structured products and index-based
derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
Forward Looking Statement
Statements made in this press release, which are not
historical in nature, constitute forward-looking statements for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. These statements include, among
others, those regarding the implications of being added to
the Russell 2000®,
Russell 3000® and Russell
Microcap® Indexes. These statements are based on
Seelos' current expectations and beliefs and are subject to a
number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Risks associated with Seelos' business include, but are
not limited to, the risk of not successfully executing its
preclinical and clinical studies, including the Proof of Concept
study of SLS-002, and not gaining marketing approvals for its
product candidates, the risk that prior clinical results may not be
replicated in future studies and trials (including the risk that
the clinical results from the planned Part 2 of the Proof of
Concept study of SLS-002 are not replicated or are materially
different from the topline clinical results of Part I of the Proof
of Concept study of SLS-002), the risks that clinical study results
may not meet any or all endpoints of a clinical study and that any
data generated from such studies may not support a regulatory
submission or approval, the risks associated with the
implementation of a new business strategy, the risks related to
raising capital to fund its development plans and ongoing
operations, risks related to Seelos' current stock price, risks
related to the global impact of COVID-19, as well as other factors
expressed in Seelos' periodic filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. Although we believe that the
expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove
correct. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable securities laws.
Contact Information
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download
multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-added-to-the-russell-2000-russell-3000-and-russell-microcap-indexes-301320629.html
SOURCE Seelos Therapeutics, Inc.